Drug Approval | September 03, 2021
Covid-19 vaccine clinical trial for people with autoimmune disease
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
The company has to approach the DCGI for approval to commence the trials
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
Subscribe To Our Newsletter & Stay Updated
